ASSESSMENT OF EXPRESSION OF ADAM17 GENE IN ACUTE LYMPHOBLASTIC LEUKEMIA IN PEDIATRIC PATIENTS .

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Clinical and Chemical Pathology, University of Alexandria

2 Department of pediatrics, Faculty of Medicine, Alexandria University

3 Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Egypt.

4 Department of Clinical and chemical pathology , Faculty of Medicine, Alexandria University

Abstract

Introduction:
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic disease characterized by the abnormal neoplastic proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other parenchymatous organs as liver, spleen and lymph nodes.The involvement of cytogenetic, molecular as well as epigenetic diagnostic criteria in the following years have acquired a pivotal crucial and critical in the refinement of diagnosis of cases of ALL. ADAM17 (TACE) is an enzyme that impacts cancer progression through its sheddase activity, which involves cleaving cell surface proteins. This process affects growth factor signaling, angiogenesis, cell adhesion, and immune system evasion. In ALL, dysregulated ADAM17 can worsen disease outcomes by influencing cell proliferation and survival, making it a potential target for new cancer therapies.
Aim:
The aim of this study was to define the diagnostic relevance of the expression of ADAM17 gene in newly diagnosed cases of ALL in Pediatric patients.
Patient and Methods:

Keywords

ALEXMED ePosters
Volume 6, Issue 4
September 2024
Pages 60-61

Files

Share

How to cite

Statistics